Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 12/20 | 0.41 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.35 |
| ▸ | KDM2B | Q8NHM5 | 2/20 | 0.35 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20103485 | 0.80 | FFAR1 (0.42) | FFAR1SLC18A2KCNH2 | |
| SCHEMBL21644868 | 0.76 | FFAR1 (0.51) | FFAR1MTNR1B | |
| SCHEMBL20103540 | 0.76 | FFAR1 (0.51) | FFAR1MTNR1B | |
| SCHEMBL20103517 | 0.76 | FFAR1 (0.51) | FFAR1MTNR1B | |
| SCHEMBL20103513 | 0.76 | FFAR1 (0.51) | FFAR1MTNR1B | |
| SCHEMBL8098541 | 0.75 | FFAR1 (0.46) | FFAR1 | |
| SCHEMBL21644922 | 0.71 | FFAR1 (0.45) | FFAR1MTNR1B | |
| SCHEMBL24645999 | 0.68 | FFAR1 (0.47) | FFAR1MTNR1B | |
| SCHEMBL20103281 | 0.68 | PTGDR2 (0.52) | FFAR1 | |
| SCHEMBL22724741 | 0.67 | FFAR1 (0.49) | FFAR1MTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10988433-B2 | Cyclohexyl GPR40 agonists for the treatment of type II diabetes | JANSSEN PHARMACEUTICA NV (BE) | 2021-04-27 | — | — | US | disclosed |
| US-20200039914-A1 | CYCLOHEXYL GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN RESEARCH & DEVELOPMENT, LLC | 2020-02-06 | — | — | US | disclosed |
| WO-2018081047-A1 | CYCLOHEXYL GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200039914-A1 | CYCLOHEXYL GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | GPR119, GPR65, GPR55 | FFAR1 16/4885SLC18A2 3165/4885KDM2B 2115/4885 |
| US-10988433-B2 | Cyclohexyl GPR40 agonists for the treatment of type II diabetes | GPR119, GPR65, GPR55 | FFAR1 16/4885SLC18A2 3165/4885KDM2B 2115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.